$SRPT
Sarepta Therapeutics,, Inc. Common Stock
XNAS•Health Care•Pharmaceutical Preparations
Sarepta Therapeutics,, Inc. Common Stock
XNAS•Health Care•Pharmaceutical Preparations
Why is SRPT down today? It is at $14.21 (-2.20%), and our scanner flagged it 141 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment SRPT spikes, and full due diligence on SRPT — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $SRPT 141 times in the last 30 days. Create a free account to track $SRPT, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on SRPT from our scanner (live price and day move above). Our scanner has fired 12 unusual-volume and momentum alerts on SRPT today, peaking at 48.9x its normal volume.
Likely catalystSarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate DevelopmentsReported Net product revenues for the third quarter 2026 totaled approximately $323.8 million, consisting of approximately $240.3 million of PMO net product revenues and $83.5 million of ELEVIDYS® net product revenueReported Continued disciplined financial execution with positive cash flow and GAAP operating loss of ($9.0) million and non-GAAP operating income of $22.9 million for the third quarter 2026Reported Updates to 2026 guidance range include raising lower end of total net product revenue by $50.0 million, driven by strong PMO performance, and lowering higher end of expense by $25.0 million, reflecting operating discipline, from an SEC filing. Read it →Latest filing13F-HRInstitutional holdings reportNov 13, 2026 · 5 days agoSources: float & market cap via Polygon · short interest via FINRA · borrow & shortability via Alpaca · SSR from Reg SHO 201 · filings & dilution via SEC EDGAR · analysts via Nasdaq.
Auto-generated from public data for research and education. Not investment advice.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Rodino-Klapac Louise Officer | Sold (automatic/other) | -21K 0.02% of company | sold 9.5% | 204K | $476K at $22.22 | Sep 4, 26 |
Rothfuss Cristin Officer | Sold (automatic/other) | -22K 0.02% of company | sold 16% | 116K | $489K at $22.22 | Sep 4, 26 |
Estepan Ian Michael Officer | Sold (automatic/other) | -25K 0.02% of company | sold 12% | 177K | $551K at $22.22 | Sep 4, 26 |
Wong Ryan Ho-Yan Officer | Sold (automatic/other) | -13K 0.01% of company | sold 9.8% | 122K | $295K at $22.22 | Sep 4, 26 |
Severino Michael Officer | Acquired (grant/award) | +756K 0.7% of company | n/a | 756K | n/a | Jul 28, 26 |
Barry Richard Director | Acquired (grant/award) | +17K 0.02% of company | added 0.6% | 2.98M | n/a | Jun 4, 26 |
Chambers Michael Andrew Director | Acquired (grant/award) | +17K 0.02% of company | added 100% | 28K | n/a | Jun 4, 26 |
Nicaise Claude Director | Acquired (grant/award) | +17K 0.02% of company | added 54% | 48K | n/a | Jun 4, 26 |
Connelly Deirdre P Director | Acquired (grant/award) | +17K 0.02% of company | added 100% | 22K | n/a | Jun 4, 26 |
Behrens M Kathleen Director | Acquired (grant/award) | +17K 0.02% of company | added 8.5% | 214K | n/a | Jun 4, 26 |
Wigzell Hans Lennart Rudolf Director | Acquired (grant/award) | +17K 0.02% of company | added 67% | 42K | n/a | Jun 4, 26 |
Mayo Stephen Director | Acquired (grant/award) | +17K 0.02% of company | added 100% | 19K | n/a | Jun 4, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.





The tickers our scanner is lighting up most over the last 48 hours.
Comparable names in pharmaceutical preparations, closest in size first.
Here is the latest on SRPT from our scanner (live price and day move above). Our scanner has fired 12 unusual-volume and momentum alerts on SRPT today, peaking at 48.9x its normal volume.
SRPT last traded at $14.21, down 2.20% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
The SRPT Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged SRPT 141 times in the last 30 days.
SRPT (Sarepta Therapeutics,, Inc. Common Stock) trades on XNAS, with a market cap of about $1.56B in the PHARMACEUTICAL PREPARATIONS sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge SRPT for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$SRPT discussion
Sign in to ask a question or join the discussion.